Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment

Antivirale Kombinationstherapie mit Interferon/Peginterferon plus Ribavirin bei Patienten mit chronischer Hepatitis C in Deutschland: ein Health Technology Assessment im Auftrag der Deutschen Agentur für Health Technology Assessment

Abstract

Objective: The purpose of this health technology assessment (HTA), commissioned by the German Agency for HTA at the German Federal Ministry of Health and Social Security, was to systematically review the evidence on effectiveness and cost-effectiveness of antiviral treatment (AVT) for initial chronic hepatitis C (CHC) and to apply these data in the context of the German health care system.

Methods: A systematic literature search was conducted to identify randomised controlled trials (RCTs), meta-analyses, and HTAs that evaluated initial AVT for CHC. A modified version of the German Hepatitis C Model (GEHMO) -- a decision-analytic Markov model -- was used to determine long-term morbidity, life expectancy, quality of life, costs and cost-effectiveness of different treatment strategies. Model parameters were derived from German databases, international RCTs, and a Cochrane Review.

Results: Overall, 9 RCTs, 2 HTA reports, 1 Cochrane review, and 2 meta-analyses examining medical effectiveness of antiviral combination therapy, as well as 7 economic evaluations, met the inclusion criteria. These studies indicate that combination therapy with peginterferon plus ribavirin produced the highest sustained virological response rates (54-61%), followed by interferon plus ribavirin with 38-54%, and interferon monotherapy with 11-21%. Based on international cost-effectiveness studies, interferon plus ribavirin is cost-effective compared to interferon monotherapy. No published articles were available regarding cost-effectiveness of peginterferon plus ribavirin. In our decision analysis, these findings were confirmed and the discounted incremental cost-effectiveness ratio for peginterferon plus ribavirin was € 9,800 per quality-adjusted life-year gained compared to interferon monotherapy (as the next best non-dominated strategy). Sensitivity analyses showed robust results across a wide range of model parameters.

Conclusions: This HTA suggests that initial combination therapy prolongs life, improves quality of life, and is cost-effective in patients with CHC. Combination of peginterferon and ribavirin is the most effective and efficient treatment strategy among the examined options.

Zusammenfassung

Ziel: Gegenstand dieses Health Technology Assessments (HTA), welches im Auftrag der Deutschen Agentur für HTA (DIMDI/Bundesministerium für Gesundheit und Soziale Sicherung) durchgeführt wurde, war die

Uwe Siebert[1]
Gaby Sroczynski[2]
German Hepatitis C Model (GEHMO) Group
HTA Expert Panel on Hepatitis C

1 Program on Health Technology Assessment and Decision Sciences, Bavarian Public Health Research and Coordinating Center, Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Germany; Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

2 Program on Health Technology Assessment and Decision Sciences, Bavarian Public Health Research and Coordinating Center, Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Germany

systematische Bewertung der medizinischen Effektivität und der Kosteneffektivität antiviraler Therapien bei therapienaiven Patienten mit chronischer Hepatitis C im Kontext des deutschen Gesundheitswesens. Methoden: Es wurde eine systematische Literaturrecherche zur Identifikation von randomisierten klinischen Studien (RCT), Metaanalysen und HTAs zur initialen antiviralen Therapie bei chronischer Hepatitis C durchgeführt. Mit einer modifizierten Version des German Hepatitis C Model (GEHMO), einem entscheidungsanalytischen Markov-Modell, wurden Langzeitmorbidität, Lebenserwartung, qualitätskorrigierte Lebensjahre (QALY), Lebenszeitkosten und das inkrementelle Kosten-Nutzwert-Verhältnis (IKNV) für verschiedene Therapiestrategien ermittelt. Die Modellparameter wurden deutschen Datenbanken, internationalen RCTs und einem Cochrane-Review entnommen.

Ergebnisse: Insgesamt erfüllten 9 RCTs, 2 HTA-Berichte, 1 Cochrane Review und 2 Metaanalysen zur medizinischen Effektivität sowie 7 ökonomische Evaluationen die Einschlusskriterien dieses HTA. Die Sustained Virological Response Raten (SVR) waren am höchsten für Peginterferon plus Ribavirin mit 54-61%, gefolgt von Interferon plus Ribavirin mit 38-54% und der Interferon-Monotherapie mit 11-21%. In internationalen Kosten-Effektivitäts-Studien wurde die Kombinationstherapie mit Interferon und Ribavirin im Vergleich zur Interferon-Monotherapie als kosteneffektiv eingeschätzt. Publizierte Studien zur Kosteneffektivität der Kombinationstherapie mit Peginterferon und Ribavirin wurden im Recherchezeitraum nicht identifiziert. Die Ergebnisse dieses Reviews wurden in unserer entscheidungsanalytischen Modellierung bestätigt. Die Kombinationstherapie mit Peginterferon und Ribavirin erzielte im Vergleich zur Interferon-Monotherapie ein IKNV von 9.800 €/QALY. In Sensitivitätsanalysen zeigten sich robuste Ergebnisse über weite Bereiche der relevanten Modellparameter.

Schlussfolgerung: Basierend auf den Ergebnissen dieses HTAs ist davon auszugehen, dass antivirale Kombinationstherapien bei therapienaiven Patienten die Lebenserwartung erhöhen, die Langzeit-Lebensqualität verbessern und als kosteneffektiv einzustufen sind. Die Kombinationstherapie mit Peginterferon und Ribavirin besitzt unter den untersuchten Therapien die höchste Effektivität und ist im Vergleich zu anderen im deutschen Gesundheitswesen akzeptierten medizinischen Verfahren als kosteneffektiv zu bewerten.

Introduction

Chronic hepatitis C (CHC) is an emerging problem in public health. Hepatitis C virus (HCV) infects an estimated 170 million persons world-wide, with 5 million in Western Europe [1]. In Germany, the prevalence of HCV has been estimated to be 0.5% and the incidence to be 5000 new infected persons per year, resulting in more than 400,000 prevalent cases of chronic hepatitis C [2], [3].

The virus imposes significant personal and social burdens on infected individuals, as well as substantial costs to society. Progression to chronic disease occurs in the majority of HCV-infected persons [4]. Approximately 20% of patients with CHC develop compensated liver cirrhosis within 20 - 30 years [5], [6], [7], [8], [9], [10], [11], [12], which is associated with high mortality risk due to liver failure.

Antiviral combination therapy with interferon alpha and ribavirin has been considered the standard of care for treatment-naïve patients with chronic hepatitis C infection and elevated alanine amino transferase (ALT) levels [5], [13], [14], but recent multinational randomised controlled clinical trials [15], [16] showed that combination therapy with peginterferon alpha and ribavirin yielded higher sustained virological response rates.

However, antiviral combination therapy is relatively expensive, raising the question of whether its clinical benefit supports the costs. With rising medical costs and limited health care budgets, attention is increasingly being focused not only on the clinical benefits of new drugs but also on their economic impact. To date no systematic evaluation of the medical benefits and economic effects of antiviral therapy for patients with CHC has been undertaken in Germany.

Therefore, the German Agency for Health Technology Assessment at DIMDI and the German Federal Ministry of Health and Social Security commissioned this health technology assessment (HTA). Its objectives were (1) to systematically review the evidence on effectiveness and cost-effectiveness of initial antiviral combination therapy in patients with CHC, (2) to develop a decision-analytic Markov model for treatment-naïve patients with CHC for

the context of the German health care system and (3) to analyse the effectiveness and cost-effectiveness of initial antiviral therapy in patients with CHC and elevated ALTs in Germany.

Research Questions

All research questions of this study were based on a population of treatment naïve patients with chronic hepatitis C and elevated ALT levels. The following specific research questions were examined.
1. How does the effectiveness regarding sustained virological response rate (SVR) compare between the evaluated antiviral treatment strategies?
2. How does the effectiveness compare between the evaluated antiviral treatment strategies regarding the following long-term outcomes?
- Compensated liver cirrhosis
- Decompensated liver cirrhosis
- Hepatocellular carcinoma
- Liver transplantation
- CHC-related mortality
- Total mortality
- Quality-adjusted life expectancy
3. What is the incremental cost-effectiveness of each antiviral therapy in comparison to the next best strategy?
4. Which antiviral therapy can be recommended as standard therapy for the German health care context according to effectiveness and cost-effectiveness?

Methods

Systematic Review

Electronic databases, HTA-information networks, and bibliographic sources were systematically searched to identify randomised controlled trials (RCT), meta-analyses, or HTA reports that evaluated initial antiviral combination therapy in patients with CHC (see appendix for search code in Notes). The time horizon of the literature search was limited from 1990 to 2002. Study quality and transferability to the German context were assessed using instruments developed by the German Scientific Working Group Technology Assessment for Health Care [17], [18], [19]. The information was qualitatively summarised in evidence tables [20]. Results are reported in country-specific currencies. To facilitate comparison across countries, all results were additionally converted to US dollars (US$) of the index year of each study. As currency conversion methods in the individual studies were poorly described, we used exchange rates expressed as national currency units per US$ instead of applying Purchasing Power Parities (PPPs) [21].

A meta-analysis of randomised clinical trials on the medical effectiveness of antiviral combination therapy with peginterferon plus ribavirin was performed using random and fixed effects models (REM, FEM). Based on the standards of the Cochrane Collaboration [22], the

pooled relative risk (RR) for the outcome "No Sustained Virological Response" with its 95% confidence interval (CI) was reported. Results were presented as forest plot.

Collaboration and HTA Expert Panel on Hepatitis C

During this HTA, collaboration was established with the following institutions:
- Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark
- Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
- Robert Koch-Institute, Berlin, Germany
- Federal Institute for Drugs and Medical Devices, Bonn, Germany
- National Association of Statutory Health Insurance Physicians, Cologne, Germany
- Hep-Net - German Network of Excellence for Viral Hepatitis

Furthermore, the HTA Expert Panel on Hepatitis C was established for this HTA. This interdisciplinary panel included members of the German Hepatitis C Model (GEHMO) Group and further experts from different areas who consulted information concerning actual unpublished data and studies and methodological issues. The list "HTA Expert Panel on Hepatitis C" (see Notes at the end of the article) gives the names, affiliations, and assigned areas of the expert panel members.

Decision Analysis

A modified version of the German Hepatitis C Model (GEHMO) was used. This model was designed to include pooled effectiveness data from meta-analyses, as well as benefits and costs, for employing different antiviral treatment strategies for patients with chronic hepatitis C. Pooled effectiveness data were derived from meta-analyses performed by the Hepato-Biliary Cochrane Group [23], [24] and additional meta-analyses were performed by the authors. GEHMO is a decision-analytic Markov model based on a previously published and validated Markov model for the natural history of disease [25], [26] and modified for the German health-care system and German hepatitis C-specific practice patterns.

The model was used to determine long-term morbidity, life expectancy, quality-adjusted life expectancy, lifetime costs, and discounted incremental cost-utility ratios (ICUR) of the following strategies: (1) no antiviral therapy, (2) interferon monotherapy (3x3 MU/week) for 48 weeks, (3) combination therapy with interferon (3x3 MU/week) and ribavirin (1000-1200 mg/day) for 48 weeks, and (4) combination therapy with peginterferon (180 µg/week for peginterferon alpha 2a; 1.5 µg/kg for peginterferon alpha 2b) plus ribavirin (800-1200 mg/day) for 48 weeks. According to the European guidelines [5], interferon monotherapy was stopped after 12 weeks and combination therapies were stopped after 24 weeks if no virolo-

Table 1: Efficacy data used in the Markov model

Antiviral treatment	VRStop	RR$_{noVRStop}$	VRETR	RR$_{noVRETR}$	SVR	RR$_{noSVR}$	Reference
Interferon monotherapy		0,68*		0,72*		0,74*	[24; 25]
Interferon plus ribavirin	55%		54%		37%		[24; 25]
Peginterferon plus ribavirin	72%**		69%		58%		[18; 32]

VRStop: Virological response rate after 12 (Interferon mono-therapy) or 24 weeks of therapy
VRETR: Virological response rate at end of treatment
SVR: Sustained virological response rate
RR$_{noVRStop}$: Relative risk for not having a virological response until 12th or 24th week
RR$_{noVRETR}$: Relative risk for not having a virological response until end of therapy
RR$_{noSVR}$: Relative risk for not having a sustained virological response
* efficacy for interferon mono-therapy: relative risk for not having a sustained virological response (RR$_{NoSVR}$) or not having a virological response until end of therapy (RR$_{NoVRETR}$) compared to combination therapy with interferon plus ribavirin
** calculated based on breakthrough rate between 24th and 48th week

gical response was observed at this time. Dosing was based on European recommendations for patients with chronic hepatitis C and European drug approved labelling [5].

Natural history data were estimated from several published studies and have been described elsewhere [25], [26]. Histological classification as mild or moderate chronic hepatitis or compensated cirrhosis was defined by the modified histology activity index of Knodell [27], [28]. For the German context, demographic and clinical parameters as well as utilities were based on original data from a quality-of-life survey in CHC patients (n=428) [29], [30]. Utility data included empirically estimated relative reductions in short-term quality-of-life due to positive HCV status (2%) and adverse events during antiviral treatment (5% for interferon plus ribavirin and 10% for peginterferon plus ribavirin).

Our model included pooled short-term outcomes (overall sustained virological response rates and respective relative risks) from recently published RCTs and meta-analyses. Relative virological response rates of interferon monotherapy and combination therapy with interferon alpha plus ribavirin were based on a recently published meta-analysis [23] and a Cochrane Review [24]. We performed a meta-analysis to derive pooled virological response rates of combination therapy with peginterferon plus ribavirin published in two randomised clinical multicentre trials [15], [16] (see Table 1).

Direct annual costs were calculated based on frequencies of inpatient and outpatient visits, diagnostic and laboratory testing, medication, and procedures related to the specific health states (Table 2). Health resource utilisation frequencies were derived from a German expert panel (n = 10) and an economic survey in chronic hepatitis C patients (n = 196). Costs were derived from healthcare databases and currently applicable pharmaceutical prices

of interferon alpha, peginterferon alpha, and ribavirin in Germany (Table 3).

A 5% deduction from pharmaceutical prices for the proportion of persons insured by the social health insurance in Germany was performed. For modelling the costs of liver transplantation, a study [31] based on German patient data for the year 1993 was used. All costs were converted to year 2002 Euros (1 Euro = 1.95583 DM) by using the medical care component of the Consumer Price Index for Germany [32]. An annual discount rate of 3% was applied to costs and effectiveness based on international recommendations [33], [34] and varied in sensitivity analyses between 0% and 10% regarding German recommendations [35].

Model Validation

The decision model was validated on three levels:
• Technical validation: 'clean up' of the software program from potential programming bugs
• Internal validation: comparison of model predictions with epidemiological and clinical data used in the model
• External validation: comparison of model predictions with published epidemiological data not used in the model

The technical validation using different routine tests (e.g. setting SVR equal for all strategies, eliminating antiviral treatment costs, eliminating CHC-related mortality, etc.) yielded the expected results. In the internal validation, all data values used were reproduced exactly by the decision model (e.g. SVR rates, progression incidences, background mortality).

In the external validation, the incidence of developing compensated liver cirrhosis in patients with mild chronic hepatitis C was adjusted for the spontaneous HCV-remission rate of 31% in patients with acute HCV-infection [36]. The model predicted a 20-year incidence of developing

Table 2: Annual treatment costs for HCV-related health states

Health state	Annual costs (€)
Mild chronic hepatitis C	125
Moderate chronic hepatitis C	128
Compensated cirrhosis	634
Diuretic-sensitive ascites	1,872
Diuretic-refractory ascites	12,714
Hepatic encephalopathy (first year)	7,856
Hepatic encephalopathy (subsequent years)	2,703
Variceal haemorrhage (first year)	12,653
Variceal haemorrhage (subsequent years)	3,380
Hepatocellular carcinoma	19,700
Liver transplantation (first year)	134,851
Liver transplantation (subsequent years)	19,503

Costs were based on frequencies of inpatient and outpatient visits, diagnostic and laboratory testing, medication, and medical procedures associated with the specific health states. All costs were converted to year 2002 Euros by using the medical care component of the Consumer Price Index of Germany [32].

Table 3: Medication prices for antiviral treatment [60]

Medication	Application and Dosage	Price (€)
Interferon α-2a	12 injectors x 3 MU	595.75
Interferon α-2b	2 pens x 18 MU	647.42
Alfacon-1	12 injectors x 9µg	569.93
Peginterferon α-2a	4 injectors x 180µg	1,321.82
Peginterferon α-2b	4 injectors x 100 µg	1,305.31
Ribavirin (Copegus)	168 capsules x 200mg	1,214.54
Ribavirin (Rebetol)	168 capsules x 200mg	1,146.82

compensated liver cirrhosis of 19% in patients with initial HCV-infection. This result is consistent with published data from prospective studies [4], [37].

As the spontaneous HCV remission rate and the incidence of liver cirrhosis have been extracted from different sources, using different values for spontaneous HCV remission could lead to a proportional deviation from the cirrhosis incidence used in the validation. However, different rates for spontaneous HCV remission would not influence results from this model because the target cohort of our analysis are patients with chronic hepatitis C.

Sensitivity Analyses

To assess the robustness of base-case results, univariate sensitivity analyses were performed for all model parameters based either on 95% confidence intervals or on ranges used in the literature. Costs were halved and doubled to obtain lower and upper limits. In addition to univariate sensitivity analyses, multivariate sensitivity analyses were performed on the entire set of disease progression rates. As it has been shown that the progression of hepatitis C observed in epidemiologic studies varies and strongly depends on the study design [8], we performed conservative sensitivity analyses with extremely low progression rates. Furthermore, we analysed a worst-case scenario using extremely conservative estimates for benefits and costs for the combination therapy with peginterferon and ribavirin.

Software

Decision analytic calculations were performed with DATA Pro for Health Care (TreeAge Software Inc., Williamstown, MA), SAS 8.1 (SAS Institute Inc., Cary, NC). Systat 10 (SPSS, Inc., Chicago, IL) was used for statistical analyses of primary data.

Table 4: Sustained virological response rates (SVR) for interferon plus ribavirin versus interferon monotherapy - primary studies.

Study	N	Treatment duration [Weeks]	SVR [%] (95% confidence interval)	
			Interferon + Ribavirin	Interferon + Placebo
Lai et al. 1996	40	48	48 (26-70)*	11 (2-35)*
McHutchison et al. 1998	912	48	38 (32-45)	13 (9-17)
Poynard et al. 1998	832	48	43 (37-49)	19 (15-24)
Mangia et al. 2001	192	48	54 (44-64)	21 (13-29)
Chemello et al. 1995	45	24	47 (22-73)*	n.a.
McHutchison et al. 1998	912	24	31 (25-37)	6 (3-9)*
Poynard et al. 1998	832	24	35 (29-41)	19 (15-24)
Reichard et al. 1998	100	24	36 (23-51)*	18 (9-32)*
Barbaro et al. 2000	428	24	43 (36-50)*	17 (13-23)*

SVR: Sustained virological response rate
* Calculations based on data in publication
n.a.: not available

Table 5: Sustained virological response rates (SVR) for peginterferon plus ribavirin versus interferon plus ribavirin.

Study	N	Treatment duration [Weeks]	SVR [%] (95% confidence interval)		p-value
			Peginterferon + Ribavirin	Interferon+ Ribavirin	
Manns et al. 2001	1016	48	54 (49-58)*	47 (42-51)*	0.01
Fried et al. 2002	897	48	56 (51-61)*	44 (39-49)*	< 0.001

SVR: Sustained virological response rate
* Calculations based on data in publication

Results

Systematic Review

Twelve studies regarding the medical efficacy of combination therapy with interferon plus ribavirin compared to interferon monotherapy were included; herein 2 HTA reports [38], [39] 1 systematic Cochrane review [24], 2 meta-analyses [23], [40] and 7 controlled randomised clinical trials [41], [42], [43], [44], [13], [14], [45]. Two controlled randomised multicentre studies [15], [16] regarding medical efficacy of combination therapy with peginterferon and ribavirin compared to interferon plus ribavirin were identified and included.

All included studies reported significantly higher SVR for combination therapy with interferon and ribavirin compared with interferon monotherapy (38-54% vs. 11-21%) (Table 4). Meta-analyses reported SVRs of 32-41% for interferon in combination with ribavirin compared to 8-16% for interferon monotherapy.

For peginterferon combined with ribavirin, multicentre clinical trials reported SVRs of 54% vs. 47% (p-value 0.01)

[16] and 56% vs. 44% (p-value < 0.001) [15] compared to standard combination therapy, respectively (Table 5). In a subgroup data analysis, one multicentre study [16] showed that patients treated with a dosage of 10.6 mg or more ribavirin per kg body weight had higher SVRs. Sixty-one percent of patients treated with peginterferon plus ribavirin compared to 48% patients treated with interferon plus ribavirin achieved a sustained virological response. The pooled relative risk for the outcome 'no sustained virological response' for the combination therapy with peginterferon plus ribavirin versus interferon plus ribavirin was 0.83 (95% CI 0.76-0.91 for fixed effects model and 0.75-0.91 for random effects model). Figure 1 shows the forest plot for the fixed effects model.

Study or sub-category	PEG-IFN+RBV n/N	IFN+RBV n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
Manns 2001	237/511	270/505		52.12	0.87 [0.77, 0.98]
Fried 2002	198/453	247/444		47.88	0.79 [0.69, 0.90]
Total (95% CI)	964	949		100.00	0.83 [0.76, 0.91]

Total events: 435 (PEG-IFN+RBV), 517 (IFN+RBV)
Test for heterogeneity: Chi² = 1.14, df = 1 (P = 0.29), I² = 12.0%
Test for overall effect: Z = 4.07 (P < 0.0001)

0.5 0.7 1 1.5 2
Favours PEG-IFN+RBV   Favours IFN+RBV

Figure 1: Meta-analysis: Forest Plot and pooled relative risk (RR) for no sustained virological response (SVR) for peginterferon plus ribavirin (PEG-IFN+RBV) versus interferon plus ribavirin (INF+RBV)

Seven studies including one HTA report [46], [47], [48], [39], [49], [50], [51] regarding cost-effectiveness of antiviral combination therapy with interferon and ribavirin in patients with chronic hepatitis C were identified in the search period of this HTA (January 1990 - December 2002), but no publications were found examining cost-effectiveness of antiviral combination therapy with peginterferon and ribavirin.

Incremental cost-effectiveness ratios varied over a wide range depending on discount rate, treatment duration, and population characteristics (Table 6). All studies considered antiviral therapy with interferon plus ribavirin seemed to be reasonably cost-effective.

For full evidence tables and results on study quality and transferability see the online HTA, the full text of which is available at www.dimdi.de [52].

German Decision Analysis

Based on our decision analysis, initial antiviral therapy compared to no treatment in patients with chronic hepatitis C saved 1.1 life years for interferon monotherapy, 2.9 life years for interferon plus ribavirin, and 4.6 life years for peginterferon plus ribavirin (Table 7), and reduced the 20-year-risk of dying from liver failure by 12% for interferon alone, 29% for interferon plus ribavirin, and 46% for peginterferon plus ribavirin (Table 8). Compared to no antiviral therapy, interferon monotherapy saved 1.2 quality-adjusted life years (QALY), while combination therapy with interferon and ribavirin saved 3.0 QALYs and peginterferon plus ribavirin saved 4.8 QALYs.

After discounting for future benefits, interferon monotherapy gained 0.53 QALYs with additional costs of € 2,800 resulting in an ICUR of € 5,300 per QALY compared to no antiviral therapy (Table 9). Moving from interferon monotherapy to interferon plus ribavirin was associated with 0.78 QALYs gained, additional costs of € 9,000, and an ICUR of 11,600 €/QALY. Compared to interferon monotherapy (as the next best non-dominated strategy), peginterferon plus ribavirin gained 1.53 QALYs and increased costs by € 14,900 yielding an ICUR of 9,800 €/QALY. Therefore, combination therapy with peginterferon plus ribavirin was the most effective treatment strategy and was more efficient than interferon plus ribavirin. To facilitate comparison with ICURs presented in Table 6, we converted the model-based ICURs for Germany to 2002 US dollars using the currency exchange rate (US$1 equals €1.07) [21]. When compared to interferon monotherapy, the ICURs of interferon plus ribavirin and peginterferon plus ribavirin were 10,800 US$/QALY and 9,200 US$/QALY, respectively.

In sensitivity analyses, results were robust when varying most relevant model parameters. Even when reducing SVR to 50%, combination therapy with peginterferon plus ribavirin was still the most effective strategy. Peginterferon plus ribavirin remained the most effective and cost-effective strategy when varying the proportion of patients with compensated cirrhosis from 0% to 52%, the propor-

Table 6: Discounted incremental cost-effectiveness-ratios (ICER) and discounted incremental cost-utility-ratios (ICUR) for combination therapy with interferon plus ribavirin (24 or 48 weeks) vs. interferon monotherapy (48 weeks) in treatment-naïve patients with chronic hepatitis C

Study	Country	Currency Year	Discount rate [%]	Therapy duration [weeks]	Age [years]	Histology	Original Currency		Converted to US$	
							ICER [costs/LY]	ICUR [costs/QALY]	ICER [US$/LY]	ICUR [US$/QALY]
Wong et al. 2000a	USA	US$ 1999	3	24	40	Mild	n.a.	7,000	n.a.	7,000
Buti et al. 2000	Spain	€ 1998	3 3 3	48 48 48	30 45 60	Mild Mild Mild	2,984 8,515 36,171	1,325 2,558 5,581	3,316 9,461 40,190	1,472 2,842 6,201
Stein et al. 2002	UK	£ 1998	6	48*	n.a.	Mild	n.a.	5,900	n.a.	9,833
Wong et al. 2000	USA	US$ 1999	3	24	40	Mod	n.a.	2,600	n.a.	2,600
Buti et al. 2000	Spain	€ 1998	3 3 3	48 48 48	30 45 60	Mod Mod Mod	880 2,172 7,575	578 1,172 2,885	978 2,413 8,417	642 1,302 3,206
Stein et al. 2002	UK	£ 1998/9	6	48*	n.a.	Mod	n.a.	2,735	n.a.	4,558
Wong et al. 2000	USA	US$ 1999	3	24	40	Cirr	n.a.	2,600	n.a.	2,600
Younossi et al. 1999	USA	US$ 1998	3	24	45	Mild+Mod	n.a.	cs	n.a.	cs
Sagmeister et al. 2001	Switzerland	€ 1998	3 3 3 3	48 48 24 24	42 42 42 42	Mild+Mod+G1 Mild+Mod+G-non-1 Mild+Mod+G1 Mild+Mod+G-non-1	n.a. n.a. n.a. n.a.	7,135 3,565 13,464 cs	n.a. n.a. n.a. n.a.	7,928 3,961 14,960 cs
Wong et al. 2000	USA	US$ 1999	3 3	24 48	40 40	Mild+Mod+Cirr Mild+Mod+Cirr	n.a. n.a.	5,400 7,700	n.a. n.a.	5,400 7,700

(Continued)

Table 6: Discounted incremental cost-effectiveness-ratios (ICER) and discounted incremental cost-utility-ratios (ICUR) for combination therapy with interferon plus ribavirin (24 or 48 weeks) vs. interferon monotherapy (48 weeks) in treatment-naïve patients with chronic hepatitis C

Study	Country	Currency Year	Discount rate [%]	Therapy duration [weeks]	Age [years]	Histology	Original Currency		Converted to US$	
							ICER [costs/LY]	ICUR [costs/QALY]	ICER [US$/LY]	ICUR [US$/QALY]
Shepherd et al. 2000	UK	£	6	24	n.a.	CHC	10,086	6,839	16,810	11,398
		n.a. [1]	6	48	n.a.	CHC	n.a.	16,180	n.a.	26,967
Stein et al. 2002	UK	£ 1998/9	6	48*	n.a.	CHC	n.a.	3,485	n.a.	5,808
Stein et al. 2002	UK	£ 1998/9	6	48	n.a.	CHC; G-1	n.a.	8,626	n.a.	14,377
			6	24	n.a.	CHC; G-non-1	n.a.	872	n.a.	1,453
Wong et al. 2000	USA	US$ 1999	3	24	40	Mild+Mod+Cirr, G-1	n.a.	11,600	n.a.	11,600
			3	24	40	Mild+Mod+Cirr, G-non-1	n.a.	cs	n.a.	cs
Sennfält et al. 2001	Sweden	US$ n.a. [2]	3	24	43	Mild+Mod+Cirr, G-1	6,800	1,400	6,800	1,400
			3	48	43	Mild+Mod+Cirr, G-1	21,900	6,000	21,900	6,000
			3	24	43	Mild+Mod+Cirr, G-non-1	cs	cs	cs	cs
			3	48	43	Mild+Mod+Cirr, G-non-1	5,200	1,800	5,200	1,800

LY: Life years, QALY: quality-adjusted life year, n.a.: not available, Mild: mild chronic hepatitis C, Mod: moderate chronic hepatitis C, Cirr: compensated cirrhosis, CHC: chronic hepatitis C, G-1: Genotype 1, G-non-1: Genotype >1, cs: cost-saving
*Therapy duration for genotype 1 (other genotypes 24 weeks).
Exchange rates expressed as national currency units per US$ were used to convert all results to US$ [21].
[1] assumed index year 1998, [2] assumed index year 1999.

Table 7: Undiscounted therapy costs and lifetime treatment costs in € (base-case analysis)

	No antiviral therapy	Interferon	Interferon + Ribavirin	Peginter-feron + Ribavirin
20-year risk (%)				
Compensated cirrhosis after mild or moderate CHC[1]	50.8	43.4	32.2	21.2
Compensated cirrhosis after mild CHC[2]	27.6	23.7	17.5	11.5
Compensated cirrhosis after initial hepatitis C[3]	19.1	16.4	12.1	8.0
Decompensated cirrhosis	21.7	19.1	15.2	11.3
Hepatocellular carcinoma	8.7	7.7	6.3	4.9
Liver transplantation[4]	2.2	1.9	1.5	1.1
Death due to liver failure	22.7	20.1	16.1	12.2
Life expectancy (years)	28.3	29.5	31.2	32.9
Quality-adjusted life expectancy (QALY)	25.3	26.5	28.3	30.0

* All values are rounded
[1] Population at risk: mild/moderate hepatitis C
[2] Population at risk: mild hepatitis C
[3] Population at risk: initial hepatitis C (including acute hepatitis C)
[4] No re-transplantations considered

Table 8: Twenty-year-risk for clinical events, life expectancy, and quality-adjusted life expectancy (undiscounted).*

Costs for	No antiviral therapy	Interferon	Interferon + Ribavirin	Peginterferon + Ribavirin
Antiviral medication		3,598	15,040	23,555
Initiation of therapy*		596	627	654
Outpatient visits + lab-tests[†]		282	355	382
Other[‡]		153	410	437
Total therapy costs		4,630	16,433	25,028
Total lifetime costs	26,923	28,228	34,946	38,578

* Including pre-treatment diagnostic tests (pregnancy test, quantitative HCV-RNA test, thyroid-stimulating hormone, thyroxine, liver biopsy) and inpatient therapy introduction.
[†] Including outpatient visits and lab-tests (routine visits), periodic tests (qualitative HCV-RNA test, thyroid-stimulating hormone, thyroxine).
[‡] Including therapy-related pregnancy tests, condoms, hormonal contraception, and abortion.

tion of male CHC-patients from 20% to 100%, or when body weight was increased by 20%.

Several sensitivity analyses were performed on progression rates. In a conservative scenario, the 20-year incidence of compensated cirrhosis was set to 7% as reported in a meta-analysis of results from community-based studies [8]. This scenario is conservative, because the study population of community-based studies included 38% of patients with normal ALT levels which is associated with a reduced risk of developing liver cirrhosis compared to our target population of CHC-patients with elevated ALT levels [53]. Figure 2 demonstrates the impact of progression on the ICUR of antiviral combination therapy. Even with a 20-year-incidence of cirrhosis of only 7%, as reported in community studies [8], peginterferon plus ribavirin was the most effective therapy and, with an ICUR of 21,100 €/QALY, was still reasonably cost-effective. When we further removed the 2% quality-of-life reduction due to HCV-infection in viral-positive CHC patients in this conservative scenario, the ICUR increased to 26,200 €/QALY.

In the worst-case scenario, which was performed to obtain extremely conservative estimates for benefits (e.g., SVR) and costs for the combination therapy with peginterferon and ribavirin, peginterferon plus ribavirin was the most effective treatment strategy and resulted in an ICUR of 27,300 €/QALY compared to the next best non-dominated strategy (i.e., interferon monotherapy).

Table 9: Base-case analysis: absolute and incremental discounted costs and efficacy, discounted incremental cost-effectiveness-ratio and discounted incremental cost-utility-ratio for different treatment strategies at annual 3% discount rate*

	No antiviral therapy	Interferon (vs. no therapy)	Interferon + Ribavirin (vs. Interferon)	Peginterferon + Ribavirin (vs. Interferon)
Costs (€)	14,800	17,600	26,600	32,500
Incremental costs (€)	–	2,800	(9,000)	14,900
Life expectancy (years)	17.97	18.45	19.19	19.90
Incremental Life expectancy (years)	–	0.48	(0.73)	1.45
Incremental cost-effectiveness-ratio (€/year)	–	5,800	(12,300)	10,300
Quality-adjusted life expectancy (QALY)	16.07	16.60	17.38	18.13
Incremental quality-adjusted life expectancy (QALY)	–	0.53	(0.78)	1.53
Incremental cost-utility-ratio (€/QALY)	–	5,300	(11,600)	9,800

* Values are rounded.
QALY: quality-adjusted life year
Values in parentheses indicate dominated situations

Figure 2: Influence of disease progression rate on the incremental cost-utility-ratio of antiviral combination therapy. Disease progression is described as 20-year incidence of compensated liver cirrhosis in initial HVC-infected patients (including acute hepatitis C).

Discussion

In this health technology assessment, a systematic evaluation of the medical efficacy and cost-effectiveness of antiviral combination therapy as an initial treatment for patients with chronic hepatitis C was performed. In addition, a modified version of the German Hepatitis C Model (GEHMO) was applied to predict the 20-year risks of CHC-related liver diseases, life expectancy, quality-adjusted life expectancy, lifetime costs, and incremental cost-utility ratio for different antiviral treatment strategies and for the German health care context.

Several randomised trials [41], [42], [43], [44], [13], [14], [45] and meta-analyses [23], [24], [40] reported combination therapy with interferon plus ribavirin to be more efficient than interferon monotherapy (SVR: 32-54% vs. 8-21%). Two randomised multicentre studies [15], [16] reported a higher SVR for peginterferon plus ribavirin compared to combination therapy with interferon plus ribavirin (54-56% vs. 44-47%).

In terms of life expectancy and quality-adjusted life expectancy combination therapy with interferon plus ribavirin was more effective and also reasonably cost-effective when compared to interferon monotherapy, based on international cost-effectiveness studies [46], [47], [48], [39], [49], [50], [51].

In our decision analysis for the context of the German health care system, initial antiviral therapy with interferon and ribavirin compared to interferon monotherapy had a discounted ICUR of 11,600 €/QALY. Compared to interferon monotherapy, peginterferon plus ribavirin cost € 14,900 and gained 1.53 QALYs, resulting in an ICUR of 9,800 €/QALY. Therefore, combination therapy with peginterferon plus ribavirin was the most effective and cost-effective treatment strategy.

Compared to other well-accepted medical interventions, e.g., hemodialysis [54] or coronary artery bypass grafts [55] with ICURs of 50,000 to 60,000 €/QALY, combination therapy with peginterferon and ribavirin can be considered as cost-effective.

As is the case with all model-based cost-effectiveness analyses, ours has several limitations due to the availability of data on the natural history of chronic hepatitis C. The risk of progression to cirrhosis is especially controversially. In a recently published review of 57 studies on the natural history of hepatitis C [8], the authors classified the identified studies into four categories of study design and used regression analysis to derive pooled progression estimates for each category. The estimated 20-year risk of cirrhosis was 24% for post-transfusion cohorts, 22% for liver clinic series, 7% for community-based cohorts, and 4% for blood donors. Adjusting for demographic and clinical characteristics explained only a small part of the heterogeneity. It has been argued that biases such as referral bias and selection bias may explain the high cirrhosis risks in liver series and post-transfusion cohorts as well as the low estimates in blood donors [7]. The fraction of patients with elevated ALT levels varied between these different settings and was as low as 62% in the community-based studies [8].

The target population of our study was a patient cohort with elevated ALT values and a mix of different histological stages as observed in clinical trials and routine clinical practice in the absence of systematic screening. Post-transfusion studies were the only category that required the presence of clinical or biochemical hepatitis, and thus may be the category that best represents the advanced disease stage of the population we studied. However, transfusion may be associated with underlying chronic disease, which itself may influence the progression of hepatitis [7]. In community-based studies, most patients had normal ALT values, and some studies included patients with acute hepatitis C. Thus, these studies do not reflect the decision context and the population we studied. However, even after reducing the progression rates of our model to the extent that 20-year cirrhosis risk was only 7% (i.e., reflecting the community-based estimate), the ICUR for combination therapy with peginterferon plus ribavirin remained below 22,000 €/QALY. This indicated the robustness regarding the optimal choice among the evaluated strategies even under very conservative assumptions.

However, the results may be different for patients with normal ALT levels, with acute hepatitis C, or in populations in which a systematic screening for HCV was performed and, therefore, most cases were detected in a very early stage of the disease. For an evaluation in these populations, the decision model and its data must be adapted to the specific context. In particular, this means that even if future studies yield good SVRs in screened patients or patients with normal ALT values, long-term effectiveness or cost-effectiveness cannot be automatically inferred from these results without additional decision analyses. For peginterferon plus ribavirin, the estimation of medical efficacy was based on only 2 studies [15], [16], the only published randomised clinical multicentre trials. However, the results of these two trials were similar, and our decision analysis results remained robust when varying the SVR in sensitivity analyses. More evidence should be retrieved from additional randomised clinical trials comparing combination therapy with peginterferon plus ribavirin to standard combination therapy.

Severe adverse events may occur more frequently in patients treated with peginterferon plus ribavirin than in patients treated with interferon plus ribavirin [15], [16]. As the absolute number of adverse events was small, and no utility data were available for each type of adverse event, we were unable to develop a micromodel for severe adverse events. Instead, we empirically estimated the overall relative reduction in quality of life due to different antiviral treatment regimens from the German CHC quality-of-life survey.

Our economic analysis likely underestimates disease-related costs for several reasons, and therefore likely underestimates treatment-related savings due to prevented future complications. First, we used variable costs and did not consider fixed costs nor costs due to productivity loss. Second, our model does not include the cost of future liver biopsies and further therapy for non-responders. Third, we did not consider histology normalisation in responders, nor reduced incidence of hepatocellular carcinoma in non-responders.

This analysis applied average age, gender distribution, genotype distribution, and histology to avoid potential biases related to patient-level variation in the different treatment groups of the trials and applied a consistent resource utilisation structure in the model and institutional assignment (where different institutions across Germany may vary in their economic efficiencies and accounting practices).

Table 10: Search Strategy

Step	Search Code
#1	interferon.ti.
#2	ribavirin.ti.
#3	hepatitis C.ti.
#4	1 and 2 and 3
#5	'Randomized Controlled Trial'.pt.
#6	*"Ribavirin"/
#7	*"Hepatitis C"/dt or *"Hepatitis C"/th or *"Hepatitis C, Chronic"/dt or *"Hepatitis C, Chronic"/th
#8	6 and 7
#9	4 and 5 and 8
#10	'not respond$'.ti.
#11	'non-respond$'.ti.
#12	nonrespond$.ti.
#13	relaps$.ti.
#14	10 or 11 or 12 or 13
#15	9 not 14
#16	Cost$
#17	"combination therapy".ti
#18	(17 and 3) or 4
#19	18 not 14
#20	19 and 16

Country to country differences in sociodemographic structure, distribution of patient's clinical characteristics, utility profiles, resource utilisation, and prices make it difficult, if not impossible, to transfer the results of our qualitative review of economic evaluations to other healthcare systems and countries [56], [57], [58], [19], [59]. However, the cost-effectiveness patterns for interferon and ribavirin in other industrialised countries were similar to the results derived from the German decision model. As none of the included economic evaluations examined the cost-utility ratio of peginterferon plus ribavirin, the German model results are currently the only data for this new treatment.

Future studies should examine the efficacy and the need for antiviral therapy in patients with normal ALT levels, with histological mild hepatitis C, and with certain risk and comorbidity profiles (e.g., HIV infection, intravenous drug users, haemophilia, etc.). All clinical trials used the sustained virological response rate as a surrogate marker for the clinical efficacy. Further epidemiological studies evaluating long-term clinical outcomes (e.g., incidence of cirrhosis, mortality) should be performed to provide more evidence on the long-term benefit of antiviral therapy. Furthermore, further research is needed regarding the natural progression of the disease considering different prognostic factors. More observational long-term studies on the natural history of hepatitis C and the medical effectiveness of different therapeutic strategies should be performed, as well as prospective studies assessing actual cost for treatment and side effects in the routine health care setting.

Conclusions

This HTA suggests that initial combination therapy for chronic hepatitis C should prolong life, improve quality-adjusted life expectancy, and be cost-effective. The combination of pegylated interferon and ribavirin is currently the most effective and efficient antiviral treatment for CHC.

However, because not all chronic hepatitis C patients will develop progressive liver disease, a thorough assessment of the eligibility and appropriateness of treatment with combination therapy requires a careful discussion between patients and physicians. This discussion must consider the demographic and clinical characteristics of the patient and the trade-offs between the expected prognosis, side effects, and the willingness to consider antiviral treatment to prevent potential future liver complications.

Notes

Appendix: Literature Search Strategy

The code in Table 10 represents the OVID search strategy used for identifying clinical and economic studies on antiviral combination therapy for chronic hepatitis C in MEDLINE and PreMEDLINE. Similar searches were performed in EMBASE, Cochrane Library, Best Evidence, NHS HTA databases (DARE, NHS EED, HTA), EconLit, Health Services Research Projects in Progress (HSRPROJ), Health Services/Technology Assessment (HSTAT), International Health Technology Assessment (IHTA), Catalog Online (CATLINE), and Science Citation Index (Science Citation

Table 11: HTA Expert Panel on Hepatitis C

Expert	Institution (for German institutions the German name is listed)
Epidemiology, Health Reporting	
Prof. Dr. Bärbel M. Kurth	Abteilung für Epidemiologie und Gesundheitsberichterstattung, Robert Koch-Institut, Berlin
Dr. Hannelore K. Neuhauser, MPH	Abteilung für Epidemiologie und Gesundheitsberichterstattung, Robert Koch-Institut, Berlin
Infectious Diseases	
PD Dr. Klaus Stark	Abteilung für Infektionsepidemiologie, Robert Koch-Institut, Berlin
Dr. Nikolai Mühlberger, MPH	Abteilung für Infektions- und Tropenmedizin der Ludwig-Maximilians-Universität-München
Gastroenterology/Hepatology	
PD Dr. Siegbert Rossol	Abteilung Innere Medizin - Gastroenterologie, Stadtkrankenhaus Rüsselsheim, Universität Mainz
Prof. Dr. Michael P. Manns	Abteilung für Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover
Prof. Dr. Stefan Zeuzem	Klinik für Innere Medizin II, Universitätskliniken des Saarlandes, Homburg/Saar
Dr. Jürgen K. Rockstroh	Medizinische Klinik und Poliklinik I, Universität Bonn
PD Dr. Markus Sagmeister	Abteilung für Innere Medizin, Landeskrankenhaus Feldkirch, Österreich
Dr. Michael Corzillius, MPH	HIV-Ambulanz, II. Medizinische Klinik, Christian-Albrechts-Universität Kiel
Systematic Reviews, Cochrane Collaboration	
Dr. Lise L. Kjaergard, MD	Cochrane Hepato-Biliary Group, Kopenhagen Trial Unit, Centre for Clinical Intervention Research H:S Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Dr. Christian Gluud, MD	Cochrane Hepato-Biliary Group, Kopenhagen Trial Unit, Centre for Clinical Intervention Research H:S Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Health Economics	
Prof. Dr. Jürgen Wasem	Alfried Krupp von Bohlen und Halbach-Stiftungslehrstuhl für Medizinmanagement, Universität Duisburg-Essen
Dr. Pamela Aidelsburger, MPH	Lehrstuhl für Allgemeine Betriebswirtschaftslehre und Gesundheitsmanagement, Ernst-Moritz-Arndt-Universität Greifswald
Dr. Franz Hessel, MPH	Alfried Krupp von Bohlen und Halbach-Stiftungslehrstuhl für Medizinmanagement, Universität Duisburg-Essen
Dr. Florian Buchner, MPH	Lehrstuhl für Allgemeine Betriebswirtschaftslehre und Gesundheitsmanagement, Ernst-Moritz-Arndt-Universität Greifswald
Pharmacoeconomics	
Dr. rer. nat. Eva-Susanne Dietrich	Referat Arzneimittel, Kassenärztliche Bundesvereinigung, Köln

(Continued)
Table 11: HTA Expert Panel on Hepatitis C

Expert	Institution (for German institutions the German name is listed)
Quality of Life, Utility Measurement	
PD Dr. Ulrike Ravens-Sieberer, MPH	Epidemiologische Forschungsgruppe Kinder- und Jugendgesundheit, Robert Koch-Institut, Berlin
Dipl.-Psych. Michael Erhardt	Epidemiologische Forschungsgruppe Kinder- und Jugendgesundheit, Robert Koch-Institut, Berlin
Prof. Dr. Monika Bullinger	Abteilung für Medizinische Psychologie, Universitätskrankenhaus Hamburg-Eppendorf, Universität Hamburg
Dr. Wolfgang Greiner	Institut für Versicherungsbetriebslehre, Universität Hannover
Prof. Dr. Graf v. der Schulenburg	Institut für Versicherungsbetriebslehre, Universität Hannover
HTA Methods	
Dr. Matthias Perleth, MPH	AOK-Bundesverband, Stabsbereich Medizin, Dependance Berlin
Donald Husereau, B.Sc.Pharm., M.Sc.	Canadian Coordinating Office for Health Technology Assessment, Ottawa, ON, Canada
Public Health	
PD Dr. Manfred Wildner, MPH	Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit und Bayerischer Forschungs- und Aktionsverbund Public Health
Dipl.-Soz. Astrid Manstetten	Bayerische Forschungs- und Koordinierungsstelle Public Health, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München
Decision-analytic Modeling	
Prof. Dr. John B. Wong	Division of Clinical Decision Making, Informatics and Telemedicine, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
Biostatistics	
Dr. Rolf Holle	Institut für Gesundheitsökonomie und Gesundheitsmanagement, GSF - Forschungszentrum für Umwelt und Gesundheit, Neuherberg
Dr. Armin Koch	Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn
Medical Informatics	
Dr. Annette Conrads-Frank	Forschungsgruppe Health Technology Assessment und Decision Sciences, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München
Medical Ethics	
Dr. Georg Marckmann	Institut für Ethik und Geschichte der Medizin, Tübingen
Health Policy and Management, Decision Makers	
Dr. Bernhard Gibis, MPH	Kassenärztliche Bundesvereinigung (KBV), Dezernat 2, Versorgungsqualität und Sicherstellung, Berlin

Index Expanded, Social Science Citation Index and Arts & Humanities Citation Index). The HTA covered documents published between 1990 and December 2002. Line #15 and line #20 represent the final codes for studies on clinical effectiveness and economic studies, respectively.

HTA Expert Panel on Hepatitis C

See Table 11.

Acknowledgements

References

1. Global Surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.

2. Robert Koch Institut. Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis B und C bis zum Jahr 2001. Epidemiol Bull 2002;44:360-76.

3. Schreier E, Höhne M. Hepatitis C - Epidemiologie und Prävention. Bundesgesundheitsblatt 2001;44:554-61.

4. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.

5. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-61.

6. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.

7. Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002;17:423-30.

8. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16.

9. Hopf U, Moller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke-Handjery A, Walter E, Blum HE, Roggendorf M, Deinhard F. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990;10:69-76.

10. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993;119:110-5.

11. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-8.

12. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.

13. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.

14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.

15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med 2002;347:975-82.

16. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.

17. Lühmann D, Siebert U, Droste S, von der Leyen U, Perleth M. Konzeption zur Anpassung und Erstellung von Technologiebewertungen in der deutschen Arbeitsgruppe Verfahrensbewertung in der Medizin. In: Toolkit. Informationsmaterial für Verfasser von HTA-Berichten. Hannover: German Scientific Working Group Technology Assessment for Health Care; 1999.

18. Siebert U, Behrend C, Mühlberger N, Wasem J, Greiner W, v. d. Schulenburg JM, et al. Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland. In: Leidl R, v. d. Schulenburg JM, Wasem J, editors. Ansätze und Methoden der ökonomischen Evaluation - eine internationale Perspektive. Baden-Baden: Nomos; 1999. p. 156-70.

19. Welte R, Leidl R. Übertragung der Ergebnisse ökonomischer Evaluationsstudien aus dem Ausland auf Deutschland: Probleme und Lösungsansätze. In: Leidl R, v. d. Schulenburg JM, Wasem J, editors. Ansätze und Methoden der ökonomischen Evaluation - eine internationale Perspektive. Baden-Baden: Nomos; 1999. p. 171-202.

20. Siebert U, Mühlberger N, Behrend C, Wasem J. Technology assessment for health care: a tool for explicitly evaluating economic studies. GMDS-Tagungsband 1999. In: GMDS: Medizinische Informatik, Biometrie und Epidemiologie. GMDS '99. 44. Jahrestagung der GMDS in Heidelberg, September 1999. München: MMV Medizin; 1999.

21. Organisation for Economic Co-operation and Development. OECD Health Data 2003: a comparative analysis of 30 countries. Paris: OECD; 2000.

22. Cochrane Collaboration. Cochrane Collaboration open learning material for reviewers. Available from: http://www.cochrane-net.org/openlearning/HTML/mod11-4.htm; 2002.

23. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001;323:1151-5.

24. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev 2002;(1):CD002234.

25. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.

26. Wong JB, Davis GL, Pauker SG, for the International Hepatitis Interventional Therapy Group. Cost-effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Hepatology 1998;28 (Suppl 4, Pt 2):591A.

27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 1994;19:1513-20.

28. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.

29. Siebert U, Greiner W, Ravens-Sieberer U, Sroczynski G, Wong J, von der Schulenburg J, et al. Preference-based quality-of-life values in patients with chronic hepatitis C: Results from the German hepatitis C quality-of-life study. J Hepatol 2003;38 Suppl 2:596.

30. Siebert U, Ravens-Sieberer U, Greiner W, Sroczynski G, Wong JB, Kuntz KM, et al. Patient-based health-related quality of life in different health stages of chronic hepatitis C [Abstract]. Hepatology 2001;34 (pt 2):222A.

31. Greiner W. Ökonomische Evaluation von Gesundheitsleistungen: Fragestellungen, Methoden und Grenzen dargestellt am Beispiel der Transplantationsmedizin. Baden-Baden: Nomos-Verlags-Gesellschaft; 1999.

32. Statistisches Bundesamt. Preisindex für Arzt-, Krankenhaus- und sonstige Dienstleistungen für die Gesundheitspflege. 2000.

33. Drummond MF, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press; 1997.

34. Gold MR, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.

35. Hannoveraner Konsensus Gruppe. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsensus. Gesundheitsökonomie und Qualitätsmanagement 1999;4:A62-A65.

36. Alter MJ, Kruskon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med 1999;341:556-62.

37. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.

38. Gebo KA, et al. Management of chronic hepatitis C. Prepared by the John Hopkins Evidence-based Practice Center under Contract No 290-97-0006. Rockeville, MD: Agency for Healthcare Research and Quality; 2002. Evidence report/technology assessment, no. 60. AHRQ publication, no. 02-E030.

39. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess (Winchester, England) 2000;4(33):1-67.

40. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19 Suppl 1:57-65.

41. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, Barbarini G. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators. J Hepatol 2000;33:448-55.

42. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23 Suppl 2:8-12.

43. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.

44. Mangi A, Villani MR, Minerva N, Leandro G, Bacca D, Cela M, Carretta V, Attino V, Ventrella F, Giangaspero F, Andriulli A. Efficacy of 5 MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol 2001;34:441-6.

45. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351(9096):83-7.

46. Buti M, Casado M, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:651-8.

47. Sagmeister M, Wong JB, Mullhaupt B, Renner E. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001;13:483-8.

48. Sennfält K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001;36:870-6.

49. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253-8.

50. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000;95:1524-30.

51. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.

52. Siebert U, Sroczynski G, unter Mitwirkung der German Hepatitis C Model (GEHMO) Group. Antiviral therapy in patients with chronic hepatitis C in Germany. Clinical and economic evaluation of the initial combination therapy with interferon/peginterferon and ribavirin. [German, original title: Antivirale Therapie bei Patienten mit chronischer Hepatitis C in Deutschland. Medizinische und ökonomische Evaluation der initialen Kombinationstherapie mit Interferon/Peginterferon und Ribavirin]. Köln: German Institute for Medical Documentation and Information; 2003 (in print). HTA Series of the German Institute for Medical Documentation and Information, commissioned by the Federal Ministry of Health and Social Security.

53. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36 (5 Suppl 1):S47-56.

54. Weinstein MC. High-priced technology can be good value for money. Ann Intern Med 1999;130:857-8.

55. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990;113:852-71.

56. Baltussen R, Ament A, Leidl R. Making cost assessments based on RCTs more useful to decision-makers. Health Policy 1996;37:163-83.

57. Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, Knill-Jones RP, de Pouvourville G, Torfs K. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992;8:671-82.

58. Haycox A, Dubois D, Butterworth M. Customising an international disease management model to the needs of individual countries. Application to upper gastrointestinal disease. Pharmacoeconomics 1998;14 Suppl 2:39-56.

59. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998;7:481-93.

60. Rote Liste Service GmbH. Rote Liste: Arzneimittelverzeichnis für Deutschland. Aulendorf: Editio Cantor Verlag; 2002.

Corresponding author:

Uwe Siebert

Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, 101 Merrimac Street, 10th floor, Boston, MA 02114-4724, USA, Phone: +1-617-724-3738, Fax: +1-617-249-1541

siebert@ibe.med.uni-muenchen.de